Loading...
•
Mar 31, 2023
Aclaris Therapeutics Q1 2023 Earnings Report
Aclaris Therapeutics reported financial results for Q1 2023 and provided a corporate update.
Key Takeaways
Aclaris Therapeutics reported a net loss of $28.2 million on total revenue of $2.5 million for the first quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $204.4 million as of March 31, 2023, and anticipates funding operations through the end of 2025.
Aclaris is advancing clinical stage development programs toward data milestones.
Topline data for zunsemetinib in rheumatoid arthritis is expected in the fourth quarter of 2023.
Topline data for zunsemetinib in psoriatic arthritis is now expected in the first half of 2024.
Topline data for ATI-1777 in atopic dermatitis is projected in the second half of 2023.
Aclaris Therapeutics
Aclaris Therapeutics
Aclaris Therapeutics Revenue by Segment
Revenue by Segment
Contract research Revenue
CapyFin.comLicensing Revenue
CapyFin.com Forward Guidance
Aclaris anticipates that its cash, cash equivalents and marketable securities as of March 31, 2023 in combination with the $26.7 million in net proceeds from sales under the ATM facility subsequent to quarter end, will be sufficient to fund its operations through the end of 2025, without giving effect to any potential business development transactions or additional financing activities.
Revenue & Expenses
Visualization of income flow from segment revenue to net income